Psilocybin, the psychoactive compound found in psychedelic mushrooms, is being studied in Phase I–III trials for treatment-resistant depression, major depressive disorder, alcohol use disorder, and end-of-life distress.
| Trial | Drug | Phase | Status | Sponsor | Conditions | Start date |
|---|---|---|---|---|---|---|
| Safety Profile of Psilocybin for Cocaine Use Disorder | Psilocybin | Early Phase 1 | Suspended | University of California, Los Angeles | Cocaine Use Disorder | Feb 1, 2029 |
| Psilocybin After Trauma Surgery for Pain | Psilocybin | Phase 1 | Not Yet Recruiting | Trent Emerick | Pain Management, Postoperative Pain | Dec 31, 2027 |
| Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder | Psilocybin | Phase 2 | Withdrawn | Johns Hopkins University | Opioid Use Disorder | Apr 1, 2027 |
| The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of Psilocybin | Psilocybin | Phase 1 | Not Yet Recruiting | Johns Hopkins University | Psilocybin Intoxication | Mar 1, 2027 |
| Psilocybin for Methamphetamine Use Disorder | Psilocybin | Phase 2 | Not Yet Recruiting | Peter Hendricks | Methamphetamine Use Disorder | Feb 1, 2027 |
| Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder | Psilocybin | Phase 1 / Phase 2 | Not Yet Recruiting | Indiana University | Treatment Resistant Depression, Substance Use Disorders | Feb 1, 2027 |
| Psilocybin for Depression in Veterans | Psilocybin | Phase 2 | Not Yet Recruiting | VA Office of Research and Development | Major Depression | Jan 1, 2027 |
| Group PACBT for Depression | Psilocybin | Phase 2 | Not Yet Recruiting | University of California, Los Angeles | Depression - Major Depressive Disorder, Psilocybin, Cognitive Behavioral Therapy | Jan 1, 2027 |
| ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder | Psilocybin | Phase 1 | Not Yet Recruiting | University of Minnesota | Borderline Personality Disorder, Borderline Personality Pathology, Depressive Symptoms, Emotion Dysregulation, Suicidal Ideation | Dec 1, 2026 |
| Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life | Psilocybin | Phase 1 | Not Yet Recruiting | Charles Raison | Aging, Longevity, Biomarkers of Aging | Dec 1, 2026 |
| Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain | Psilocybin | Phase 2 | Not Yet Recruiting | Yale University | Chronic Low Back Pain (CLBP), Physical Therapy, Psilocybin | Dec 1, 2026 |
| Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder | Psilocybin | Phase 2 | Not Yet Recruiting | Brigham and Women's Hospital | Alcohol Use Disorder | Nov 15, 2026 |
| NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy | Psilocybin | Phase 2 | Not Yet Recruiting | M.D. Anderson Cancer Center | Psilocybin, Neuropathy | Nov 4, 2026 |
| Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation | Psilocybin | Phase 1 | Recruiting | Brown University | Phase I | Nov 1, 2026 |
| Psilocybin Therapy for Methamphetamine Use Disorder and HIV | Psilocybin | Phase 2 | Not Yet Recruiting | Nicky Mehtani, MD, MPH | Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV) | Nov 1, 2026 |
| Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study | Psilocybin | Phase 1 | Recruiting | Oregon Health and Science University | Chronic Pelvic Pain | Nov 1, 2026 |
| Psilocybin Efficacy With or Without Pimavanserin Pretreatment | Psilocybin | Phase 1 / Phase 2 | Recruiting | Johns Hopkins University | Mood (Psychological Function), Well Being, Mood, Healthy | Oct 30, 2026 |
| Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin | Psilocybin | Phase 2 | Recruiting | National Institute on Aging (NIA) | Alzheimer's Disease | Oct 29, 2026 |
| Feasibility of Incorporating a Standardized Substance Use Measure With Linked-Brief Intervention Into Routine Psychosocial Care of Adult Childhood Cancer Survivors | Psilocybin | N/A | Recruiting | St. Jude Children's Research Hospital | Survivors of Childhood Cancer, Substance Use | Oct 1, 2026 |
| Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study | Psilocybin | Phase 1 | Not Yet Recruiting | University of Wisconsin, Madison | Well-Being, Psychological, Psychedelic Experiences | Oct 1, 2026 |
| Psilocybin Microdosing on Cognition, Mood and Quality of Life | Psilocybin | Early Phase 1 | Not Yet Recruiting | Yale University | Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI | Oct 1, 2026 |
| Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids | Psilocybin | Phase 2 | Not Yet Recruiting | Roswell Park Cancer Institute | Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm | Sep 15, 2026 |
| Psilocybin for Treatment of OCD-2 | Psilocybin | Phase 1 / Phase 2 | Not Yet Recruiting | Francisco A Moreno | Obsessive - Compulsive Disorder | Sep 8, 2026 |
| Mindfulness-based Psilocybin Therapy for PTSD | Psilocybin | Phase 2 | Recruiting | Anthony P King | Post Traumatic Stress Disorder, Depression - Major Depressive Disorder | Sep 1, 2026 |
| Evaluating the Efficacy of a Vocational Counseling Intervention to Improve Occupational Functioning and Employment Quality Among Veterans With Mental Health and Substance Use Disorders | Psilocybin | N/A | Recruiting | VA Office of Research and Development | Unemployment | Sep 1, 2026 |
| Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD | Psilocybin | Phase 2 | Recruiting | NYU Langone Health | Alcohol Use Disorder | Sep 1, 2026 |
| The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function | Psilocybin | Phase 1 / Phase 2 | Not Yet Recruiting | Manoj Doss | Healthy | Sep 1, 2026 |
| Psilocybin as a Novel Therapy for Residual Anhedonia | Psilocybin | Phase 1 | Recruiting | NYU Langone Health | Anhedonia, Emotional Blunting | Sep 1, 2026 |
| The Effects of Psilocybin on Social Connectedness | Psilocybin | Phase 1 | Not Yet Recruiting | Yale University | Loneliness, Grief | Aug 31, 2026 |
| Psilocybin-Assisted Therapy for Intergenerational Trauma | Psilocybin | Phase 2 | Recruiting | Rachel Yehuda | Psychological Stress, Depression, Anxiety | Aug 28, 2026 |
| Psilocybin Administration With 5-HT1a Blockade | Psilocybin | Early Phase 1 | Recruiting | Johns Hopkins University | Psychedelic Effects in Healthy Volunteers | Aug 12, 2026 |
| Psilocybin to Treat Depression in Spinal Cord Injury | Psilocybin | Phase 1 / Phase 2 | Recruiting | James J. Peters Veterans Affairs Medical Center | Spinal Cord Injury, Depression - Major Depressive Disorder, Veteran | Aug 6, 2026 |
| Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression | Psilocybin | Phase 3 | Recruiting | VA Office of Research and Development | Major Depression | Aug 3, 2026 |
| Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS) | Psilocybin | Early Phase 1 | Not Yet Recruiting | NYU Langone Health | IBS - Irritable Bowel Syndrome | Aug 1, 2026 |
| The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease | Psilocybin | Phase 2 | Recruiting | Yale University | Depression, Parkinson's Disease (PD) | Jul 10, 2026 |
| Psilocybin as a Treatment for Chronic Pain in Smokers | Psilocybin | Early Phase 1 | Recruiting | Yale University | Smokers With Chronic Pain | Jul 6, 2026 |
| Study of Psilocybin Under Anesthesia Controlled by EEG | Psilocybin | Phase 2 | Not Yet Recruiting | Stanford University | Major Depression | Jul 1, 2026 |
| Psilocybin-Assisted Therapy | Psilocybin | Phase 2 | Recruiting | Emory University | PTSD | Jun 8, 2026 |
| A Study of Psychedelics in Healthy Older Adults With Low Well-being | Psilocybin | Phase 1 | Recruiting | Jennifer Mitchell | Anhedonia in Healthy Volunteers, Older Adults (50-90 Years) | Jun 1, 2026 |
| Psilocybin-Assisted Therapy as a Treatment for Depression | Psilocybin | Phase 2 | Not Yet Recruiting | Washington University School of Medicine | Depression | Jun 1, 2026 |
| Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD | Psilocybin | Phase 2 | Recruiting | Sunstone Medical | Post Traumatic Stress Disorder, PTSD | May 23, 2026 |
| Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies | Psilocybin | Phase 2 | Active Not Recruiting | University of Washington | Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm | May 19, 2026 |
| Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. | Psilocybin | Phase 1 | Recruiting | Francisco A Moreno | Obsessive-Compulsive Disorder | May 18, 2026 |
| A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) | Psilocybin | Phase 3 | Recruiting | Definium Therapeutics US, Inc. | Major Depressive Disorder | May 10, 2026 |
| Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder | Psilocybin | Phase 1 | Recruiting | University of New Mexico | PTSD | May 1, 2026 |
| Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression | Psilocybin | N/A | Recruiting | Massachusetts General Hospital | Treatment Resistant Depression (TRD) | Apr 17, 2026 |
| Mystical Experiences Without Psychedelics and How Integration Improves Well-Being in Adults | Psilocybin | N/A | Not Yet Recruiting | Baylor University | Healthy Adult Participants | Apr 1, 2026 |
| Safety and Tolerability Trial of Psilocybin in Healthy Older Adults | Psilocybin | Phase 1 | Recruiting | University of Colorado, Denver | Healthy Volunteer, Older Adults (65-85 Years) | Apr 1, 2026 |
| Psilocybin for Prolonged Grief Disorder | Psilocybin | Early Phase 1 | Recruiting | University of Virginia | Prolonged Grief Disorder | Mar 24, 2026 |
| Nen ŨnkUmbi/EdaHiYedo Plus (We Are Here Now Plus): a Multi-level Intervention to Reduce Health Disparities Among American Indian Youth | Psilocybin | N/A | Recruiting | Montana State University | Healthy, Condom Use, Mental Health, Substance Use (Drugs, Alcohol) | Mar 23, 2026 |
| Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD | Psilocybin | Phase 1 | Active Not Recruiting | Scottsdale Research Institute | PTSD | Mar 20, 2026 |
| Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects | Psilocybin | Phase 1 | Completed | GH Research Ireland Limited | Healthy Adult | Mar 18, 2026 |
| Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability | Psilocybin | Phase 1 | Recruiting | Johns Hopkins University | Stroke, Chronic Stroke, Intracerebral Haemorrhage, Intracerebral Haemorrhage (ICH), Intracerebral Hemorrhage Basal Ganglia, Ischemic Stroke, Ischemic Stroke and Hemorrhagic Stroke, Hemiparesis After Stroke, Hemiplegia Following Ischemic Stroke, Hemiplegia and Hemiparesis, Hemiplegia and/or Hemiparesis Following Stroke, Middle Cerebral Artery Stroke | Feb 9, 2026 |
| Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder | Psilocybin | Phase 2 | Recruiting | T. John Winhusen, PhD | Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe | Jan 29, 2026 |
| Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter | Psilocybin | Phase 2 | Not Yet Recruiting | NYU Langone Health | Stuttering | Jan 15, 2026 |
| RCT of Psilocybin-assisted CBT for Depression | Psilocybin | Phase 1 / Phase 2 | Recruiting | University of California, Los Angeles | Major Depressive Diorder | Jan 5, 2026 |
| Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer | Psilocybin | Phase 2 | Recruiting | Alan Davis | Lung Non-Small Cell Carcinoma, Unipolar Depression | Jan 1, 2026 |
| Psilocybin for Opioid Use Disorder (OUD) | Psilocybin | Phase 2 | Recruiting | NYU Langone Health | Opioid Use Disorder | Dec 17, 2025 |
| Integrated PTSD and Chronic Pain Treatment | Psilocybin | N/A | Recruiting | Weill Medical College of Cornell University | PTSD, Chronic Pain | Dec 8, 2025 |
| Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression | Psilocybin | Phase 2 | Recruiting | VA Office of Research and Development | Chronic Low Back Pain, Depression | Dec 3, 2025 |
| A Phase 2A Trial of DT402 for Autism Spectrum Disorder | Psilocybin | Phase 2 | Recruiting | Definium Therapeutics US, Inc. | Autism Spectrum Disorder, ASD | Dec 3, 2025 |
| Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults | Psilocybin | Phase 1 | Recruiting | University of California, Berkeley | Aging | Nov 1, 2025 |
| Augmented Momentary Personal Ecological Risk Evaluation | Psilocybin | N/A | Terminated | University of Washington | Suicidal Ideation, Self Harm | Sep 25, 2025 |
| PRoMiSS: Psilocybin and the Role of Music in Set and Setting | Psilocybin | Phase 1 | Recruiting | Johns Hopkins University | Psilocybin, Music Intervention | Aug 12, 2025 |
| The RECAP2 Study: Midazolam and Psilocybin | Psilocybin | Phase 1 | Recruiting | University of Wisconsin, Madison | Psilocybin | Aug 7, 2025 |
| Mindfulness-assisted Psychedelic Therapy | Psilocybin | Phase 2 | Recruiting | University of Southern California | Mental Health | Jul 30, 2025 |
| Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) | Psilocybin | Phase 3 | Enrolling By Invitation | Cybin IRL Limited | Major Depressive Disorder | Jul 18, 2025 |
| Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality | Psilocybin | Phase 2 | Recruiting | The University of Texas Health Science Center, Houston | Bipolar II Disorder, Depression, Bipolar, Suicidality | Jul 7, 2025 |
| Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial | Psilocybin | Phase 2 | Recruiting | University of Iowa | Alcohol Use Disorder, Alcohol Dependence, Alcohol Abuse | Jun 12, 2025 |
| Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD) | Psilocybin | Phase 2 | Active Not Recruiting | Nathan Brashares Sackett | Alcohol Use Disorder (AUD), PTSD | Jun 1, 2025 |
| Psilocybin With Intracranial Neural Sensing | Psilocybin | Phase 1 | Enrolling By Invitation | Joshua Woolley, MD, PhD | Chronic Pain | Jun 1, 2025 |
| Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) | Psilocybin | Phase 1 | Recruiting | Yale University | Opioid Use Disorder | May 28, 2025 |
| TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors | Psilocybin | Phase 2 | Recruiting | M.D. Anderson Cancer Center | Depression, Anxiety, Cancer | May 23, 2025 |
| Mechanistic Studies of Psilocybin in Headache Disorders | Psilocybin | Early Phase 1 | Recruiting | Yale University | Migraine | May 19, 2025 |
| Investigation to Understand and Optimize Psilocybin | Psilocybin | Phase 2 | Recruiting | Charles Raison | Depression | May 13, 2025 |
| Psilocybin Brain Stimulation and Imaging Pilot Study | Psilocybin | Phase 1 | Completed | Johns Hopkins University | Healthy Volunteers | Apr 18, 2025 |
| A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge) | Psilocybin | Phase 3 | Active Not Recruiting | Definium Therapeutics US, Inc. | Major Depressive Disorder | Apr 14, 2025 |
| Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis | Psilocybin | Early Phase 1 | Recruiting | Johns Hopkins University | Amyotrophic Lateral Sclerosis | Apr 9, 2025 |
| Gathering Online for Dialogue and Discussion to Enhance Social Support | Psilocybin | N/A | Recruiting | RTI International | Alcohol Misuse, HIV, Sexually Transmitted Infections, Pre-exposure Prophylaxis | Apr 7, 2025 |
| Psilocybin for Methamphetamine Addiction | Psilocybin | Early Phase 1 | Recruiting | Kevin Murnane | Methamphetamine Use Disorder | Apr 4, 2025 |
| Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism | Psilocybin | N/A | Active Not Recruiting | Healing Advocacy Fund | Alcohol Use Disorder | Mar 5, 2025 |
| Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV | Psilocybin | Phase 2 | Completed | Nicky Mehtani, MD, MPH | Methamphetamine Use Disorder | Mar 4, 2025 |
| Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder | Psilocybin | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | Major Depressive Disorder | Feb 25, 2025 |
| Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder | Psilocybin | N/A | Recruiting | Spark Biomedical, Inc. | Opioid Withdrawal, Opioid Use Disorder | Feb 19, 2025 |
| Investigation of Psychedelic Effects in Psychoactive Substances | Psilocybin | Phase 1 | Recruiting | Johns Hopkins University | Psychedelic Effects in Healthy Volunteers | Feb 5, 2025 |
| State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma | Psilocybin | Phase 2 | Recruiting | Baylor College of Medicine | PTSD | Jan 30, 2025 |
| The ENHANCE Study: taVNS and Psilocybin | Psilocybin | Phase 1 | Recruiting | University of Wisconsin, Madison | Healthy, Psychedelic Experiences, Vagus Nerve Stimulation | Jan 27, 2025 |
| Pragmatic Trial of Psilocybin Therapy in Palliative Care | Psilocybin | Phase 2 | Recruiting | Charles S. Grob, M.D. | Demoralization | Jan 19, 2025 |
| Psilocybin-Assisted Therapy for Physician Well-Being and Burnout | Psilocybin | Phase 1 / Phase 2 | Recruiting | University of California, San Diego | Burnout, Burnout, Healthcare Workers | Jan 13, 2025 |
| Psilocybin rTMS for Treatment Resistant Depression | Psilocybin | Phase 2 | Recruiting | University of Texas at Austin | Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression, Depression | Jan 10, 2025 |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) | Psilocybin | Phase 3 | Active Not Recruiting | Definium Therapeutics US, Inc. | Generalized Anxiety Disorder | Dec 11, 2024 |
| Safety for Home Administration of Microdose Psilocybin Use | Psilocybin | Phase 1 | Completed | Johns Hopkins University | Psychedelic Experiences | Dec 6, 2024 |
| Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence | Psilocybin | Phase 1 | Recruiting | University of Colorado, Denver | Breast Cancer, Ovarian Cancer | Nov 21, 2024 |
| A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer | Psilocybin | Phase 1 | Completed | University of Washington | Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm | Nov 19, 2024 |
| Study of Psilocybin for Anorexia in Young Adults | Psilocybin | Phase 2 | Recruiting | Marissa Raymond-Flesch, MD, MPH | Anorexia Nervosa | Nov 18, 2024 |
| Psilocybin-assisted Treatment for Cannabis Use Disorder | Psilocybin | Phase 1 | Recruiting | Johns Hopkins University | Cannabis Use Disorder | Nov 8, 2024 |
| Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers | Psilocybin | Phase 2 | Recruiting | Robin Carhart-Harris, PhD, MA | Healthy Participants With Lower-than-average Mental Well-being | Oct 20, 2024 |
| Open-Label Psilocybin Study in Transdiagnostic Population | Psilocybin | Phase 1 | Recruiting | Yale University | Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms, PTSD, Substance Use, Substance Use Disorder (SUD), OCD | Oct 17, 2024 |
| Optimizing Microdosing and Meditation | Psilocybin | N/A | Withdrawn | National University of Natural Medicine | Meditation, Microdosing | Oct 1, 2024 |
| Psilocybin in Cancer Pain Study | Psilocybin | Phase 2 | Recruiting | Yvan Beaussant, MD, MSci | Opioid-Related Disorders, Pain Management, Pain Management and Care, Advanced Cancer, Advanced Cancers | Sep 23, 2024 |
| The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder | Psilocybin | Phase 3 | Recruiting | Sharmin Ghaznavi | Major Depressive Disorder | Sep 10, 2024 |
| Psilocybin Therapy for Depression in Parkinson's Disease | Psilocybin | Phase 2 | Recruiting | Joshua Woolley, MD, PhD | Parkinson Disease, Depression | Aug 19, 2024 |
| Low-Income Group Psilocybin Assisted Therapy for Depression | Psilocybin | N/A | Completed | Matthew Hicks | Depression | Aug 1, 2024 |
| Psilocybin for Treatment-Resistant Depression | Psilocybin | Phase 2 | Completed | University of Colorado, Denver | Major Depressive Disorder, Anhedonia, Treatment Resistant Depression | Jul 8, 2024 |
| A Study of Psilocybin for PTSD | Psilocybin | Phase 1 | Active Not Recruiting | Johns Hopkins University | Post Traumatic Stress Disorder | Jun 7, 2024 |
| Couples Motivational Interviewing to Reduce Drug Use and HIV Risk in Vulnerable Male Couples | Psilocybin | N/A | Recruiting | Hunter College of City University of New York | Substance Use, HIV Infections | May 25, 2024 |
| Ketamine-assisted Therapy for Advanced GI Cancer | Psilocybin | Phase 4 | Terminated | Brian Anderson, MD | Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization | May 17, 2024 |
| Building Social and Structural Connections for the Prevention of Opioid Use Disorder Among Youth Experiencing Homelessness | Psilocybin | N/A | Recruiting | Ohio State University | Opioid Use Disorder, Dual Diagnosis, Housing Problems, Mental Disorder in Adolescence, Risk Behavior, Homelessness | May 6, 2024 |
| Mindful Self-Compassion to Address PTSD and Substance Use in Unhoused Women | Psilocybin | N/A | Completed | University of California, Los Angeles | Posttraumatic Stress Disorder (PTSD), Anxiety, Depression - Major Depressive Disorder | May 5, 2024 |
| Psilocybin in Chronic Low Back Pain and Depression | Psilocybin | Phase 1 | Recruiting | Johns Hopkins University | Chronic Low-back Pain, Depression | Apr 22, 2024 |
| Psilocybin-Assisted Therapy in Treatment-Resistant Depression | Psilocybin | Phase 3 | Active Not Recruiting | University of North Carolina, Chapel Hill | Refractory Depression, Treatment Resistant Depression | Apr 19, 2024 |
| Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy | Psilocybin | Phase 2 | Recruiting | M.D. Anderson Cancer Center | Depression, Anxiety, Psilocybin-Assisted Psychotherapy, Advanced Cancer | Apr 16, 2024 |
| Psilocybin for Major Depressive Disorder (MDD) | Psilocybin | Phase 3 | Active Not Recruiting | Usona Institute | Depressive Disorder, Major | Mar 13, 2024 |
| Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain | Psilocybin | Phase 1 | Recruiting | University of California, Berkeley | Perception Disorders | Mar 8, 2024 |
| Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder | Psilocybin | Phase 2 | Recruiting | Johns Hopkins University | Opioid Use Disorder | Feb 8, 2024 |
| Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder | Psilocybin | Phase 2 | Active Not Recruiting | Peggy C Nopoulos | Alcohol Use Disorder | Feb 2, 2024 |
| Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS) | Psilocybin | Phase 2 | Active Not Recruiting | TRYP Therapeutics | Irritable Bowel Syndrome | Jan 17, 2024 |
| Psilocybin Therapy for Chronic Low Back Pain | Psilocybin | Phase 1 / Phase 2 | Active Not Recruiting | Joshua Woolley, MD, PhD | Chronic Low-back Pain | Dec 1, 2023 |
| Consciousness, Psilocybin, and Well-Being | Psilocybin | Phase 1 | Completed | University of Wisconsin, Madison | Healthy, Psychedelic Experiences, Sleep | Nov 7, 2023 |
| 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder | Psilocybin | Phase 2 | Recruiting | Johns Hopkins University | Tobacco Use Disorder | Nov 1, 2023 |
| Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder | Psilocybin | Phase 2 | Completed | University of Chicago | Borderline Personality Disorder, Major Depressive Disorder | Nov 1, 2023 |
| Psilocybin-facilitated Treatment for Chronic Pain | Psilocybin | Early Phase 1 | Recruiting | University of Alabama at Birmingham | Fibromyalgia, Primary | Nov 1, 2023 |
| Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer | Psilocybin | Phase 2 | Active Not Recruiting | Sunstone Medical | Cancer, Major Depressive Disorder | Oct 23, 2023 |
| Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia | Psilocybin | Phase 2 | Completed | Kevin Boehnke | Fibromyalgia | Sep 27, 2023 |
| Northwest Therapies Trauma Psilocybin Study Compassionate Use Study | Psilocybin | Phase 1 | Unknown | NWTraumatherapies | Trauma, Nervous System | Sep 3, 2023 |
| Test of the Better Together Intervention | Psilocybin | N/A | Completed | Johns Hopkins Bloomberg School of Public Health | Substance Use | Sep 1, 2023 |
| Exploratory Study of Low Dose Psilocybin | Psilocybin | Early Phase 1 | Withdrawn | University of Alabama at Birmingham | Demoralization | Aug 15, 2023 |
| Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention | Psilocybin | N/A | Recruiting | Shirish S Barve | Alcohol Use Disorder, Risk Behavior, Health, Dysbiosis, HIV Infections | Aug 1, 2023 |
| Neural and Physiological Correlates of Psychedelic Sub-states | Psilocybin | Phase 1 | Active Not Recruiting | Robin Carhart-Harris, PhD, MA | Psychedelic Experiences, Neuroimaging, Healthy Volunteers | Jul 31, 2023 |
| Effects of Repeated Psilocybin Dosing in OCD | Psilocybin | Phase 1 | Active Not Recruiting | Yale University | Obsessive-Compulsive Disorder | Jul 20, 2023 |
| PET Synaptogenesis After Psilocybin In DEpression Recovery | Psilocybin | Phase 2 | Withdrawn | Washington University School of Medicine | Major Depressive Disorder, Anhedonia | Jul 1, 2023 |
| Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer | Psilocybin | Phase 1 / Phase 2 | Completed | University of Washington | Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm | Jun 27, 2023 |
| Psilocybin-assisted CBT for Depression | Psilocybin | Phase 1 | Completed | University of California, Los Angeles | Major Depressive Disorder | Jun 27, 2023 |
| Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention | Psilocybin | N/A | Recruiting | University of Maryland, College Park | Polysubstance Addiction, Opioid Medication Assisted Treatment, Treatment Adherence, Retention in Care, Substance-Related Disorders | Jun 15, 2023 |
| Bioavailability Study of Psilocybin in Normal Adults | Psilocybin | Phase 1 | Withdrawn | University of Wisconsin, Madison | Healthy | Jun 1, 2023 |
| Reducing Drug Use in Justice-Involved Emerging Adults | Psilocybin | N/A | Completed | Chestnut Health Systems | Substance-Related Disorders | May 26, 2023 |
| Psilocybin Therapy in Advanced Cancer | Psilocybin | Phase 2 / Phase 3 | Recruiting | NYU Langone Health | Advanced Cancer | May 24, 2023 |
| Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA | Psilocybin | N/A | Active Not Recruiting | University of Alabama at Birmingham | Hiv, Alcohol Problem | May 4, 2023 |
| Effectiveness of an Evidence-based Stepped Care System for Alcohol and Other Drug Use Problems Among Congolese Refugees in Zambia | Psilocybin | N/A | Completed | Columbia University | Alcohol and Substance-Related Mental Disorders | Apr 26, 2023 |
| Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers | Psilocybin | Phase 1 | Completed | University of Nebraska | Pancreas Cancer, Biliary Tract Cancer, Psychological Distress, Gastrointestinal Cancer | Apr 10, 2023 |
| Evaluating the Efficacy of Annual CHTC Retesting Among Male Couples at High Risk of HIV Infection | Psilocybin | N/A | Enrolling By Invitation | Hunter College of City University of New York | HIV Infections | Apr 1, 2023 |
| Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder | Psilocybin | Phase 1 | Terminated | University of Wisconsin, Madison | Methamphetamine Use Disorder, Substance-Related Disorders, Chemically-Induced Disorders, Substance Use Disorders, Stimulant-Use Disorder | Mar 3, 2023 |
| Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD | Psilocybin | Phase 3 | Active Not Recruiting | COMPASS Pathways | Treatment Resistant Depression | Feb 14, 2023 |
| A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder | Psilocybin | Phase 2 | Active Not Recruiting | COMPASS Pathways | Major Depressive Disorder | Jan 30, 2023 |
| Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD | Psilocybin | Phase 3 | Completed | COMPASS Pathways | Treatment Resistant Depression | Jan 24, 2023 |
| PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout | Psilocybin | Phase 1 | Completed | University of Utah | Depression, Burnout, Professional | Jan 2, 2023 |
| Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder | Psilocybin | Phase 2 | Completed | Ohio State University | PTSD, Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, Trauma and Stressor Related Disorders, Mental Disorder | Jan 1, 2023 |
| Effects of Psilocybin in Obsessive Compulsive Disorder | Psilocybin | Early Phase 1 | Active Not Recruiting | Johns Hopkins University | Obsessive-Compulsive Disorder | Nov 28, 2022 |
| Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain | Psilocybin | Phase 1 | Completed | Emory University | Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Nov 1, 2022 |
| Psilocybin-assisted Therapy for Phantom Limb Pain | Psilocybin | Phase 1 | Active Not Recruiting | University of California, San Diego | Phantom Limb Pain | Oct 3, 2022 |
| The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD | Psilocybin | Phase 2 | Withdrawn | Massachusetts General Hospital | Treatment-Resistant Major Depressive Disorder | Sep 15, 2022 |
| Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder | Psilocybin | Phase 1 / Phase 2 | Active Not Recruiting | Portland VA Research Foundation, Inc | Amphetamine-Related Disorders | Jul 7, 2022 |
| Effects of Psilocybin in Post-Treatment Lyme Disease | Psilocybin | Phase 1 | Completed | Johns Hopkins University | Post-Treatment Lyme Disease, Chronic Lyme Disease, Lyme Disease, Chronic | Jul 1, 2022 |
| An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics | Psilocybin | Phase 1 | Completed | Usona Institute | QTc Interval, Pharmacokinetics | Jun 22, 2022 |
| The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | Psilocybin | Phase 2 | Completed | COMPASS Pathways | Post Traumatic Stress Disorder | Jun 10, 2022 |
| Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder | Psilocybin | N/A | Completed | Spark Biomedical, Inc. | Opioid-use Disorder, Opioid Withdrawal | May 27, 2022 |
| Comparing the Effects of Psilocin and Psilocybin in Healthy Adults | Psilocybin | Phase 1 | Unknown | University of California, San Francisco | Healthy | May 26, 2022 |
| Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations | Psilocybin | N/A | Completed | Yale University | Opioid Use Disorder, Infectious Disease, Risk Reduction Behavior, Substance Use, Substance Abuse, Stimulant Use Disorder | Mar 31, 2022 |
| Examining the Feasibility and Acceptability of a Tailored Version of a Mindfulness-Based Intervention (MBI) Among Youth Experiencing Homelessness (YEH) | Psilocybin | N/A | Completed | The University of Texas Health Science Center, Houston | Stress, Emotional | Mar 28, 2022 |
| The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation | Psilocybin | Phase 2 | Completed | Sheppard Pratt Health System | Treatment Resistant Depression, Suicidal Ideation | Mar 28, 2022 |
| Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder | Psilocybin | Phase 2 | Completed | TRYP Therapeutics | Binge Eating Disorder | Mar 16, 2022 |
| Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care | Psilocybin | Phase 2 | Completed | Yvan Beaussant, MD, MSci | Hospice, Psilocybin, Demoralization, Terminal Illness, Cancer-related Problem/Condition, Psychotherapy, Terminal Cancer, Cancer Terminal | Mar 9, 2022 |
| Frontline Clinician Psilocybin Study | Psilocybin | Phase 3 | Completed | University of Washington | Burnout, Caregiver, Burnout, Professional, COVID-19, Depression, Post Traumatic Stress Disorder, Moral Injury | Mar 3, 2022 |
| Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought | Psilocybin | Phase 1 / Phase 2 | Recruiting | Johns Hopkins University | Healthy | Mar 3, 2022 |
| Psilocybin Therapy for Depression in Bipolar II Disorder | Psilocybin | Phase 2 | Active Not Recruiting | University of California, San Francisco | Bipolar II Disorder | Jan 28, 2022 |
| Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome | Psilocybin | N/A | Unknown | Nova Mentis Life Science Corp | Autism Spectrum Disorder, Fra(X) Syndrome | Nov 1, 2021 |
| Expanding the Potential of Couples HIV Testing: Adjunct Modules to Reduce Drug Use Among Vulnerable Male Couples | Psilocybin | N/A | Completed | Hunter College of City University of New York | Substance Use, HIV Infections | Oct 13, 2021 |
| Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer | Psilocybin | Early Phase 1 | Completed | University of Utah | Cancer | Oct 4, 2021 |
| Visual Surround Suppression and Perceptual Expectation Under Psilocybin | Psilocybin | Phase 1 | Terminated | University of Minnesota | Perception Disturbance, Visual Suppression, Psychedelic Experiences | Aug 30, 2021 |
| Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease | Psilocybin | Phase 2 | Completed | Joshua Woolley, MD, PhD | Parkinson Disease, Depression, Anxiety | Aug 15, 2021 |
| Repeat Dosing of Psilocybin in Migraine Headache | Psilocybin | Phase 1 | Completed | Yale University | Migraine Headache | Aug 10, 2021 |
| A Phase 3 Study of NE3107 in Probable Alzheimer's Disease | Psilocybin | Phase 3 | Completed | BioVie Inc. | Alzheimer Disease | Aug 5, 2021 |
| Pilot Test of Parent-Focused Cannabis-Related Actions and Practices Intervention for Adolescent Marijuana Abuse | Psilocybin | N/A | Completed | Oregon Research Institute | Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate | Jun 1, 2021 |
| Precision Functional Brain Mapping in Psilocybin | Psilocybin | Early Phase 1 | Completed | Washington University School of Medicine | Psilocybin | Jun 1, 2021 |
| Pilot RECAP Study in Healthy Volunteers | Psilocybin | Phase 1 | Completed | University of Wisconsin, Madison | Psychedelic Experiences, Amnesia | May 21, 2021 |
| Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy | Psilocybin | Phase 2 | Completed | University of California, San Diego | Anorexia Nervosa | May 1, 2021 |
| Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder | Psilocybin | Phase 2 | Active Not Recruiting | Johns Hopkins University | Major Depressive Disorder, Alcohol Use Disorder | Apr 14, 2021 |
| Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease | Psilocybin | Early Phase 1 | Recruiting | Johns Hopkins University | Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment | Mar 24, 2021 |
| An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) | Psilocybin | Phase 2 | Unknown | Sheppard Pratt Health System | Treatment Resistant Depression | Mar 1, 2021 |
| The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. | Psilocybin | Phase 2 | Unknown | Sheppard Pratt Health System | Treatment Resistant Depression | Mar 1, 2021 |
| Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder | Psilocybin | Phase 2 | Completed | New York State Psychiatric Institute | Body Dysmorphic Disorders | Feb 26, 2021 |
| iSTART: A Campus & Community Initiative for Services in Tec-health | Psilocybin | N/A | Completed | California State University, Northridge | Substance Use, Binge Drinking, Marijuana Use, Alcohol Drinking, Prescription Opioid Misuse, Illicit Drug Use | Feb 20, 2021 |
| Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder | Psilocybin | Phase 2 | Active Not Recruiting | Keith Heinzerling | Alcohol Use Disorder | Feb 18, 2021 |
| Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine | Psilocybin | Phase 1 | Recruiting | University of Wisconsin, Madison | Opioid Use Disorder | Jan 13, 2021 |
| The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder | Psilocybin | Phase 2 | Unknown | Maryland Oncology Hematology, PA | Major Depressive Disorder | Sep 1, 2020 |
| Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment | Psilocybin | Phase 1 | Unknown | Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd | Corneal Neovascularization | Aug 26, 2020 |
| The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression | Psilocybin | Phase 2 | Completed | COMPASS Pathways | Treatment Resistant Depression | Aug 10, 2020 |
| Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU) | Psilocybin | N/A | Completed | COMPASS Pathways | Treatment Resistant Depression | Jul 20, 2020 |
| Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder | Psilocybin | N/A | Active Not Recruiting | Philadelphia College of Osteopathic Medicine | Opioid Use Disorder | Jul 15, 2020 |
| PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder | Psilocybin | N/A | Terminated | Usona Institute | Major Depressive Disorder | Jun 30, 2020 |
| A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health | Psilocybin | Phase 4 | Completed | Field Trip Health | Depression, Anxiety, Post Traumatic Stress Disorder | Mar 13, 2020 |
| Patient Doctor Lies | Psilocybin | N/A | Completed | University of Utah | Patient Lying, Privacy Statements, Risk Statements, Benefit Statements, Patient Lie Detection | Feb 12, 2020 |
| Social Media Intervention for Cannabis Use in Emerging Adults | Psilocybin | N/A | Completed | University of Michigan | Cannabis Use | Feb 3, 2020 |
| A Study of Psilocybin for Major Depressive Disorder (MDD) | Psilocybin | Phase 2 | Completed | Usona Institute | Depressive Disorder, Major | Jan 23, 2020 |
| Y2Prevent: Preventing Drug Use and HIV Through Empowerment, Social Support and Mentorship (Y2P) | Psilocybin | N/A | Completed | Children's Hospital Los Angeles | HIV, Drug Use | Jan 22, 2020 |
| Effects of Psilocybin in Anorexia Nervosa | Psilocybin | Phase 1 | Completed | Johns Hopkins University | Anorexia Nervosa | Aug 26, 2019 |
| Effects of Drugs on Responses to Brain and Emotional Processes | Psilocybin | Early Phase 1 | Completed | University of Chicago | Autism Spectrum Disorder, Healthy | Aug 8, 2019 |
| HIV+ Substance Users Released From Jail | Psilocybin | N/A | Completed | University of Texas Southwestern Medical Center | HIV/AIDS, Substance Use Disorders | May 29, 2019 |
| Mood Effects of Serotonin Agonists Extended | Psilocybin | Phase 1 | Completed | University of Chicago | Healthy | Apr 20, 2019 |
| Effects of Psilocybin in Concussion Headache | Psilocybin | Phase 1 | Terminated | Yale University | Post-Traumatic Headache | Mar 28, 2019 |
| The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression | Psilocybin | Phase 2 | Completed | COMPASS Pathways | Treatment Resistant Depression | Mar 1, 2019 |
| Psilocybin for Treatment of Obsessive Compulsive Disorder | Psilocybin | Phase 1 | Completed | University of Arizona | Obsessive-compulsive Disorder (OCD) | Jan 2, 2019 |
| Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study. | Psilocybin | Phase 1 | Completed | Yale University | Obsessive-Compulsive Disorder | Nov 13, 2018 |
| Project PRIDE (Promoting Resilience In Discriminatory Environments) | Psilocybin | N/A | Completed | University of Houston | Human Immunodeficiency Virus, Sexually Transmitted Infections, Anxiety, Depression, Substance Use Disorders | Nov 9, 2018 |
| Effectiveness & Implementation of a Behavioral Intervention for Adherence and Substance Use in HIV Care in South Africa | Psilocybin | N/A | Completed | University of Maryland, College Park | Human Immunodeficiency Virus, Alcohol-Related Disorders, Drug Use | Jul 30, 2018 |
| Mood Effects of Serotonin Agonists | Psilocybin | Phase 1 | Completed | University of Chicago | Healthy | May 1, 2018 |
| Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder | Psilocybin | Phase 1 | Active Not Recruiting | Yale University | Major Depressive Disorder | Feb 27, 2018 |
| Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors | Psilocybin | Phase 1 | Completed | Joshua Woolley | Distress, Depression, Grief | Jan 5, 2018 |
| Harnessing Placebo Effects in Methadone Treatment | Psilocybin | N/A | Completed | University of Maryland, Baltimore | Opioid-use Disorder, Opioid-Related Disorders | Dec 5, 2017 |
| Project MADD - NIH Underage DUI and Ride | Psilocybin | N/A | Completed | Penn State University | Underage Drinking, Driving Under the Influence, Drinking, Teen | Nov 17, 2017 |
| Psilocybin for the Treatment of Migraine Headache | Psilocybin | Phase 1 | Completed | Yale University | Migraine Headache | Nov 1, 2017 |
| Developing SUPPORT, a Community-Driven, Recovery-Oriented System of Care | Psilocybin | N/A | Completed | Indiana University | Substance Use | Oct 23, 2017 |
| Increasing Caregiver Engagement in Juvenile Drug Courts | Psilocybin | N/A | Completed | Medical University of South Carolina | Substance Abuse | Oct 13, 2017 |
| Pilot Study Comparing Two Versions of Group Cognitive-behavioral Indicated Prevention Programs | Psilocybin | N/A | Completed | Oregon Research Institute | Depressive Symptoms | Oct 10, 2017 |
| Effects of Psilocybin in Major Depressive Disorder | Psilocybin | Phase 2 | Completed | Johns Hopkins University | Major Depressive Disorder | Aug 10, 2017 |
| Persisting Effects of Psilocybin | Psilocybin | Phase 1 / Phase 2 | Completed | Johns Hopkins University | Healthy | Jul 1, 2017 |
| Iwin: Individual Well-Being Navigator | Psilocybin | N/A | Completed | Pro-Change Behavior Systems | Other Drug Substance Abuse | Jun 17, 2017 |
| Adolescents With Substance Use Disorders Transitioníng From Residential Treatment to the Community | Psilocybin | N/A | Completed | Brown University | Substance Use, Adolescent Behavior | Apr 1, 2017 |
| IMPAACT 2002: Cognitive Behavioral Therapy and Medication Management for Treatment of Depression in US Youth With HIV | Psilocybin | N/A | Completed | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | HIV, Depression | Mar 6, 2017 |
| Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD | Psilocybin | Phase 2 | Completed | Multidisciplinary Association for Psychedelic Studies | Posttraumatic Stress Disorder | Jan 2, 2017 |
| Psilocybin for the Treatment of Cluster Headache | Psilocybin | Phase 1 | Completed | Yale University | Cluster Headache | Dec 5, 2016 |
| Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence | Psilocybin | N/A | Completed | Kaiser Permanente | Opiate Substitution Treatment | Dec 1, 2015 |
| Motivational Coaching to Enhance Mental Health Engagement in Rural Veterans | Psilocybin | N/A | Completed | VA Office of Research and Development | Mental Health, Rural Health, Veterans Health | Oct 1, 2015 |
| Implementation Research for Vulnerable Women in South Africa | Psilocybin | N/A | Completed | RTI International | HIV, Substance Abuse | Sep 1, 2015 |
| Understanding Substance Use and Incident HIV/STI Among Young Black MSM | Psilocybin | N/A | Completed | Emory University | HIV, Substance Abuse | Jul 1, 2015 |
| Psilocybin-facilitated Treatment for Cocaine Use | Psilocybin | Phase 2 | Completed | University of Alabama at Birmingham | Cocaine-Related Disorders | May 1, 2015 |
| The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals | Psilocybin | Phase 1 | Completed | NYU Langone Health | Religious or Spiritual Problem | Apr 1, 2015 |
| Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion | Psilocybin | Phase 1 | Completed | Johns Hopkins University | Healthy | Mar 1, 2015 |
| Pilot Study of Entacapone for Methamphetamine Abuse | Psilocybin | Early Phase 1 | Completed | Oregon Health and Science University | Methamphetamine Dependence | Jun 1, 2014 |
| A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence | Psilocybin | Phase 2 | Completed | NYU Langone Health | Alcohol Dependence | Jun 1, 2014 |
| Young Women's Health CoOp (Cooperative) in Cape Town | Psilocybin | N/A | Completed | RTI International | HIV, Substance Abuse | May 1, 2014 |
| Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators | Psilocybin | Phase 1 | Completed | Johns Hopkins University | Healthy | May 1, 2014 |
| Effects of Hallucinogens and Other Drugs on Mood and Performance | Psilocybin | Phase 1 | Completed | Johns Hopkins University | Healthy | Apr 1, 2014 |
| Substance Use and Sexual Risk Reduction Intervention for Homeless Youth | Psilocybin | N/A | Completed | RAND | Substance Use, Sexual Risk Behavior | Jan 1, 2014 |
| Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators | Psilocybin | Phase 1 | Completed | Johns Hopkins University | Psilocybin, Hallucinogens, Pharmacologic Actions, Central Nervous System Agents, Therapeutic Uses, Psychotropic Drugs | May 1, 2013 |
| A Web-Based Intervention to Prevent Drug Abuse Among Adolescent Girls | Psilocybin | N/A | Completed | Columbia University | Drug Abuse Prevention | Mar 1, 2013 |
| Preventing Drug Abuse Among Hispanic Adolescents | Psilocybin | N/A | Completed | Columbia University | Drug Abuse | Sep 1, 2012 |
| Family and Adolescent Motivational Incentives for Leveraging Youth | Psilocybin | N/A | Completed | Oregon Research Institute | Substance-Related Disorders | Jul 1, 2012 |
| Integrating Substance Abuse Assessment & Intervention in Primary Care Settings | Psilocybin | N/A | Completed | Treatment Research Institute | Drug Use, Alcohol Use | Jun 1, 2012 |
| A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users | Psilocybin | Phase 1 | Completed | Cephalon | Drug Abuse | Mar 1, 2012 |
| Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma | Psilocybin | Phase 2 | Withdrawn | Multidisciplinary Association for Psychedelic Studies | Anxiety, Stage IV Melanoma | Jan 1, 2012 |
| Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence | Psilocybin | Phase 2 | Completed | University of New Mexico | Alcohol Dependence | Jan 1, 2012 |
| Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain | Psilocybin | Phase 3 | Completed | Pfizer | Chronic Noncancer Pain | Dec 1, 2010 |
| Conversion to Embeda With Rescue Trial | Psilocybin | Phase 4 | Terminated | Pfizer | Chronic Disease, Pain | Aug 1, 2010 |
| Impact of Group Motivational Interviewing and In-Home-Messaging-Devices for Dually Diagnosed Veterans | Psilocybin | N/A | Completed | VA Office of Research and Development | Alcohol Dependence, Dual Diagnosis, Drug Dependence | May 3, 2010 |
| Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma | Psilocybin | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Multiple Myeloma | Jan 15, 2010 |
| Psilocybin and Spiritual Practice | Psilocybin | Phase 1 | Completed | Johns Hopkins University | Healthy | Aug 1, 2009 |
| Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine] | Psilocybin | N/A | Completed | California Pacific Medical Center Research Institute | Healthy | Jan 1, 2009 |
| Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study | Psilocybin | N/A | Completed | Johns Hopkins University | Nicotine Dependence | Sep 1, 2008 |
| Caffeine and Cocaine | Psilocybin | Phase 1 / Phase 2 | Completed | Virginia Commonwealth University | Cocaine Dependence | Apr 1, 2008 |
| Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma | Psilocybin | Phase 1 / Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Multiple Myeloma and Plasma Cell Neoplasm | Nov 1, 2007 |
| Psychopharmacology of Psilocybin in Cancer Patients | Psilocybin | Phase 2 | Completed | Johns Hopkins University | Depressive Symptoms, Anxiety, Cancer | Apr 1, 2007 |
| Neurological Influences on Drug Prevention Intervention | Psilocybin | Phase 1 / Phase 2 | Completed | University of Florida | Youths At-risk for Drug Use/Abuse | Jan 1, 2005 |
| Youth Drug Abuse Family and Cognitive-Behavioral Therapy | Psilocybin | Phase 2 | Completed | University of Florida | Drug Abuse | Jan 1, 2005 |
| Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety | Psilocybin | Phase 1 / Phase 2 | Completed | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Anxiety | Apr 1, 2004 |
All psychedelic clinical trials · MDMA clinical trials
Active psilocybin studies focus on treatment-resistant depression, major depressive disorder, alcohol and tobacco use disorder, end-of-life distress in cancer patients, PTSD, and obsessive-compulsive disorder.
Psilocybin research spans Phase I through Phase III. Several depression programs have reached Phase III, the final stage typically required before an FDA new drug application.
Psilocybin remains a Schedule I substance federally. Oregon and Colorado have created state-regulated supervised access programs, and a growing number of cities have deprioritized enforcement. Track the current status on PoliPsy’s legislation pages.
Open any listing to view its ClinicalTrials.gov record, which lists study sites, recruitment status, and investigator contact details for each location.
Approval depends on Phase III results and FDA review timelines. Psilocybin has received Breakthrough Therapy designation for depression, which accelerates review but does not guarantee approval or set a fixed date.